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Reactivation of CMV is a common complication following
allogeneic haematopoietic SCT and is associated with
signiﬁcant morbidity and mortality. The relative impor-
tance of the CD4þ and CD8þ components of the CMV-
speciﬁc immune response in protection from reactivation is
unclear. The CMV-speciﬁc CD4þ and CD8þ immune
response was measured at serial time points in 32 patients
following allogeneic HSCT. Intracellular cytokine stain-
ing following CMV lysate stimulation and HLA-peptide
tetramers were used to determine CMV-speciﬁc CD4þ
and CD8þ responses, respectively. A deﬁcient CMV-
speciﬁc CD4þ T-cell immune response within the ﬁrst
30–50 days post transplant was associated with high risk
of viral reactivation. Patients with combined impairment
of the CD4þ and CD8þ immune response within the
ﬁrst 100 days were susceptible to late viral reactivation.
The frequency of CMV-speciﬁc CD4þ T cells correlated
with CMV-speciﬁc CD8þ T cells, comprising 10% of
the whole T-cell repertoire. Early CMV-speciﬁc CD4þ
T-cell reconstitution was dominated by effector memory
cells with normal levels of IL-2 resuming 6 months
following transplantation. In summary, both CD4 and
CD8 CMV-speciﬁc immune reconstitution is required for
protection from recurrent activation. Measurement of the
magnitude of the CMV-speciﬁc CD4þ immune response
is useful in managing viral reactivation following HSCT.
Bone Marrow Transplantation (2009) 43, 853–861;
doi:10.1038/bmt.2008.403; published online 22December 2008
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Introduction
Allogeneic haematopoietic SCT is a powerful strategy for
the treatment of many haematological disorders. The
cellular immune response is impaired for many months
post-HSCT and contributes to serious morbidity and
mortality from infectious complications.1 In particular,
CMV seropositivity remains an important risk factor for
transplant-related mortality after sibling donor and
matched unrelated donor haematopoietic stem cell recipi-
ents,2,3 particularly in the setting of T-cell-depleted
conditioning regimens. The development of effective T-cell
immunity is important for the control of CMV infection
and disease. A strong association has been found between
the lack of CMV-speciﬁc CD8þ T cells and the develop-
ment of CMV disease after transplantation.4,5 In another
study the recovery of CMV-speciﬁc CD8þ T cells to levels
of 410 cells/ml was associated with protection from CMV
disease.6 Although CD8þ CTL have been considered
as the predominant antiviral effector cells, there is an
increasing interest in the role of CD4þ T cells in
controlling and maintaining the cellular immune response.
It has been shown that infusion of CMV-speciﬁc CD8þ
T-cell clones in allogeneic transplants leads to detectable
CD8 responses in vivo but the magnitude of the responses
declines in those who lack a detectable CMV-speciﬁc CD4
response.7 A correlation between CD4 deﬁciency and CMV
reactivation has been seen in patients with HIV infection
and following solid organ transplantation.8 In renal
transplant recipients the development of CMV-speciﬁc
CD4þ T-cell immunity before virus-speciﬁc CD8þ
expansion was associated with asymptomatic control of
primary CMV viraemia. In contrast, symptomatic disease
was observed only in patients who exhibited delayed CMV-
speciﬁc CD4 immunity.9 In HSCT patients a low lympho-
cyte count and CD4þ T-cell count of less than 40 per ml at
3 months post transplant have been demonstrated as risk
factors for development of late CMV disease.10 Hakki
et al.11 also showed that low CD4 (o100 per ml) and CD8
(o50 per ml) T-cell counts at this time point are associated
with poor CMV-speciﬁc immunity. The functional poten-
tial of the cellular immune response is also critical and
dysfunctional Ag-speciﬁc CD8þ T cells have been found
as risk factors for CMV reactivation.12 These data suggest
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that both a low absolute T-cell count and poor Ag-speciﬁc
immune reconstitution are predictive of protection from
viral reactivation but were measured at 3 months post
transplant and not at earlier time points. Avetysian et al.
have recently reported that the total T-cell response to
CMV Ag at 4 weeks post-HSCT is inversely correlated with
viral load and Lilleri have suggested an absolute CD4 and
CD8 T-cell response at day 60 which may confer protection
against viraemia in young patients.13,14 Here we have
looked at the CD4þ and CD8þ T-cell response to CMV
at several time points following SCT, including an early 30
day analysis, to see if earlier detection of poor Ag-speciﬁc
T-cell immunity can predict for CMV reactivation.
Patients and methods
Patients
The study group consisted of 32 allogeneic HSCT recipients
at the QE hospital in Birmingham in which either the donor
or the recipient, or both were CMV seropositive and were
recruited from January 2002 to December 2003 (Table 1).
Patients gave informed consent for the study approved by
the South Birmingham Ethics Committee. The patients had
an age range between 21 and 60 years with a median of 42
at the time of transplantation. Of the patients, 23 had
sibling donors whereas 9 had volunteer matched unrelated
donors (MUD). Seventeen patients (53.2%) underwent
myeloablative conditioning consisting of CY and TBI
except for one patient who received a melphalan and TBI
regimen. The non-myeloablative conditioning regimens
consisted of BEAM (BCNU 300mg/m2 for 1 day, Etopo-
side 200mg/m2/day for 4 days, ara C 200mg/m2/day for 4
days. Melphelan 140mg/m2/day for 1 day)/Campath (n¼ 6;
18.7%), ﬂudarabine/melphalan/Campath (n¼ 7; 28.1%) or
BU/CY (n¼ 2; 6.3%)). CMV reactivation was routinely
monitored by quantitative PCR twice weekly up to 100
days, weekly up to 6 months and then as clinically
indicated. The sensitivity of this assay was 400 copies/ml.
Nineteen patients had CMV reactivation in the ﬁrst 3
months post transplantation and were termed as early
reactivation. Three patients had late reactivation in
addition to early reactivation and this occurred between
days 100 and 180. Sixteen patients (50%) suffered from
GVHD (acute, chronic or both).
MoAb
The following MoAb were used in this study: anti-IFN-g
(FITC, PE), anti-IL-2 (FITC, PE), mouse IgG2a (FITC,
PE), mouse IgG1 (FITC, PE), anti-CD49d and anti-CD28
(BD Biosciences, Oxford, UK); anti-CD4 (ECD, PC5),
anti-CD8 (FITC), anti-CD3 (PE), anti-CD69 (PC5), mouse
IgG1 (ECD, TC; Beckman Coulter, High Wycombe, UK);
anti-CD8 (TC; Caltag Medsystems, Buckingham, UK).
Assessment of CMV-speciﬁc CD4þ T-cell responses
CMV-speciﬁc CD4þ T-cell frequency was determined
according to the previously described method.15 Brieﬂy,
sodium-heparinized whole blood was aliquoted into 15ml
propylene tubes. Costimulatory mAbs, anti-CD28 and
anti-CD49d, were added to the samples at a 1 mg/ml ﬁnal
concentration. Patient samples were divided into no
treatment (unstimulated), SEB (Sigma-Aldrich, Poole,
UK) (positive control) and CMV lysate (Microbix Bio-
system Inc., Toronto, Canada). The culture tubes were
incubated at 37 1C in a humidiﬁed 5% CO2 atmosphere for
a total of 6 h in the presence of 10 mg/ml of the cytokine
secretion inhibitor, brefeldin A (Sigma-Aldrich), for the last
4 h of culture. EDTA (Sigma-Aldrich) was then added to a
ﬁnal concentration of 2mM for 15min at room tempera-
ture. In some experiments, the cultures were stored
overnight at 4 1C before EDTA treatment. After EDTA
treatment, the RBC were lysed and leucocytes ﬁxed with
1FACS lysing solution (BD Biosciences) for a 10min
incubation at room temperature. The cells were washed in
PBS containing 0.5% BSA (Sigma-Aldrich), 0.1% sodium
azide (Fisher, Loughborough, UK) (wash buffer) and
Table 1 Clinical characteristics of HSCT patients
Patients age (years): median (range) 41.8 (21–60)
Donors age (years): median (range) 44.1 (37–67)
Gender, number (%)
Male 18 (56.3)
Female 14 (43.7)
Underlying disease, number (%)
AML 11 (34.4)
ALL 2 (6.3)
CML 7 (21.8)
CLL 1 (3.1)
NHL 6 (18.7)
HD 2 (6.3)
Myeloma 2 (6.3)
MDS 1 (3.1)
Median follow up time (day) 201
Transplant type, number (%)
Sibling 23 (71.9)
Unrelated donor 9 (28.1)
Conditioning regimen, number (%)
CY/TBI 16 (50)
Mel/TBI 1 (3.1)
BEAM/CAM 6 (18.7)
Flu/Mel/CAM 7 (28.1)
BU/CY 2 (6.3)
Source of stem cell, number (%)
BM 3 (9.4)
PB 29 (90.6)
GVHD, number (%)
Yes 16 (50)
No 16 (50)
CMV reactivation (PCR) (%)
Early reactivation only 15 (46.8)
Early and late reactivation 4 (12.6)
None 13 (40.6)
Patients/donor CMV status, number (%)
P/P 17 (53.1)
P/N 11 (34.4)
N/P 4 (12.5)
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permeabilized by incubation with 1FACS permeabiliza-
tion buffer (BD Biosciences) for 10min at room tempera-
ture. The cells then were washed in wash buffer and
subsequently stained with directly conjugated mAbs for
30min at room temperature in the dark. After staining, the
cells were washed, ﬁxed in 1% paraformaldehyde (Fisher)
in PBS and stored at 4 1C in the dark until ﬂow cytometric
analysis. Four-colour ﬂow cytometric analysis was
performed on a Beckman Coulter XL-MCL machine
(Beckman Coulter). Data was analysed using WinMDI
software (Scripps Institute, La Jolla, CA, USA) whereby
lymphocytes were gated on FSC/SSC and CD4/CD3 and
then displayed as dot plots of cytokine (IL-2/IFN-g) vs
CD69 ﬂuorescence to determine frequency of cytokine-
positive and CD69-positive cells. Background intracellular
isotype staining was subtracted from IFN-g and IL-2
responses for both unstimulated and stimulated PBMC.
Spontaneous cytokine production from unstimulated
PBMC was then subtracted from CMV-lysate stimulation
to yield actual frequency of CMV-speciﬁc T cells.
Enumeration was examined using IFN-g production
primarily but all IL-2 producing cells produced IFN-g.
The absolute number of CMV-speciﬁc CD4þ T cells was
calculated using total lymphocyte count, frequency of
CD4þ T cells in lymphocyte and CD3þ gate and the
frequency of cytokine-positive cells.
Cell staining with tetramers
CMV tetramers derived from pp65, immediate early Ag
(IE-1) and pp50 proteins were produced using a previously
described method.16 Tetramers used in this study were
HLA-A2 restricted (pp65495–503, NLV, IE-1316–324, VLE),
-B7 restricted (pp65417–426, TPR, IE-188–96, QIK), -A1
restricted (pp50245–253, VTE, pp65363–373, YSE) and -B8
restricted (2 natural variants of IE-1199–207, ELK, ELR).
PBMC (5 105) were incubated with 0.1–0.5mg of PE-
conjugated tetramer at 37 1C for 15min. After washing with
wash buffer, the cells were resuspended and incubated with
CD8 mAb for 30min at 4 1C. The cells were washed and
analysed on the FACS immediately or ﬁxed in 2%
paraformaldehyde (Fischer) for later analysis. The absolute
number of tetramer-positive cells was quantitated using
total lymphocyte count, frequency of CD8þ T cells in the
lymphocyte gate and frequency of tetramer-positive cells in
the CD8þ T-cell subset. In subjects with more than one
CMV-speciﬁc response, the sum of the tetramer-positive
cells was made.
Statistical methods
All statistical analyses were performed using Prism
(Graphpad, San Diego, CA, USA). To identify associations
in the data, Pearson’s w2-test was used for categorical
variables (Continuity adjustment and Fisher’s exact
test were used as appropriate). The non-parametric
Mann–Whitney U-test for comparison of two groups, and
the Kruskal–Wallis test followed by the Dunn’s post-test
for more than two samples were used to compare groups of
continuous measurements. For correlation analyses the
Spearman rank test was used. A P-value of less than 0.05
was considered statistically signiﬁcant.
Results
A higher frequency of CMV-speciﬁc CD4þ T cells
between days 30 and 50 post-HSCT affords protection from
CMV reactivation
CMV reactivation occurred only when the patient was
CMV seropositive (Patient (P)/Donor (D)þ : 0/4; Pþ /
D: 7/11; Pþ /Dþ : 12/17; Po0.05) but was not inﬂuenced
by the type of donor, the development of GVHD or the
conditioning regimen. CMV-speciﬁc CD4 responses were
measured by CMV lysate stimulation followed by IL-2 and
IFN-g intracellular cytokine staining on all 32 HSCT
patients (MFI average 72.3±11.9 s.d.). Where sufﬁcient
cells were available, 25 patients were also analysed for
CMV-speciﬁc CD8 responses by HLA-class I CMV
tetramers. Assays were performed on serial samples
collected from 30 to 390 days post-HSCT.
Of the 32 patients, 19 had at least one episode of CMV
reactivation following HSCT; their serostatus, condition-
ing, donor type, day of reactivation and immune recon-
stitution are presented in Table 2. The majority of
reactivation episodes occurred between days 30 and 50
post-HSCT, and the CMV-speciﬁc CD4þ and CD8þ
T-cell response was measured during this time. Immune
function was also determined at days 80–100 and at days
180–200 in all patients (Figure 1). Between days 30 and 50,
the patients who experienced at least one episode of CMV
reactivation had a markedly reduced CMV-speciﬁc CD4 T-
cell count (median 0.4 (0.01–7.8) cells/ml) in comparison to
patients who did not reactivate (6.5 (0.01–34.9) cells/ml;
P¼ 0.03; Figure 1a). The CMV-speciﬁc CD8þ T-cell
count was threefold lower, although NS in patients
with an episode of viral reactivation (10.2 (0.01–169) vs 32
(0.03–250) cells/ml; Figure 1b). The CMV-speciﬁc CD4þ
and CD8þ T-cell responses in patients with or without
viral reactivation did not differ between days 80 and 100
nor between days 180 and 200 (Figures 1a and b).
A lower frequency of CD4þ and CD8þ CMV-speciﬁc
T cells within the ﬁrst 100 days post-SCT is associated with
recurrent CMV reactivation
Late CMV reactivation is an increasing concern with SCT
and has been reported in up to 30% of patients in some
cohorts.17 Five patients experienced more than one episode
of CMV reactivation in this study (Table 2). Patients with
recurrent viral reactivation had a signiﬁcantly lower
number of CMV-speciﬁc CD4þ T cells within the ﬁrst
100 days post transplant compared to patients with only
one reactivation; however between days 30 and 50 this was
NS because samples were not collected from all the ﬁve
patients. Within this group the median peak level of CMV-
speciﬁc CD4þ T cells during the ﬁrst 100 days was 0.4
(0.01–10) cells/ml, which is the same value that was recorded
for reactivation during the ﬁrst 50 days (Figure 1a).
Patients who did not suffer more than one episode of viral
reactivation exhibited an increase in the CD4þ T-cell
response to a median of 10 (0.2–103) cells/ml within 100
days (P¼ 0.01; Figure 2a). A similar proﬁle was seen for
CMV-speciﬁc CD8þ T cells with a median of only 0.26
(0.02–17) CMV-speciﬁc cells/ml being seen in patients with
CMV-specific T-cell reconstitution post-HSCT
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multiple reactivation episodes compared to a value over
180-fold higher (48 (0.03–262) cells/ml) in patients with only
one episode (P¼ 0.02; Figure 2b).
The CMV-speciﬁc T-cell response comprises 10% of the
T-cell pool and is correlated with the total lymphoid cell count
To determine if the total CD4 and CD8 T-cell count could
act as a surrogate marker for prediction of CMV
reactivation, the number of CMV-speciﬁc CD4þ and
CD8þ T cells was then correlated with these subsets
(Figures 3a and b, respectively). A strong positive correla-
tion was observed between the magnitude of the CMV-
speciﬁc CD4þ T-cell count and the total CD4 count
(P¼ 0.001; Figure 3a). Interestingly the peak total CD4
count was 60% lower in patients who exhibited CMV
reactivation compared to those without reactivation
(median 68 (4.4–385) vs 165 (3.3–607); P¼ 0.05). A similar
correlation was observed for the CMV-speciﬁc CD8þ and
total CD8 T-cell counts (Po0.0001; Figure 3b). The CMV-
speciﬁc immune response comprised approximately 10% of
the total CD4 and CD8 lymphoid response.
The number of CMV-speciﬁc CD4þ and CMV-speciﬁc
CD8þ T cells are highly correlated during immune
reconstitution
The number of CMV-speciﬁc CD4þ T cells was then
compared with the number of CMV-speciﬁc CD8þ T cells
as determined by HLA-peptide tetramer staining
(Figure 3c). A signiﬁcant positive correlation was observed
between the CMV-speciﬁc CD4þ and CMV-speciﬁc
CD8þ T-cell count (P¼ 0.001), which were also broadly
comparable in magnitude.
The CMV serostatus of the recipient and donor inﬂuence
the frequency and magnitude of CMV-speciﬁc T-cell
reconstitution
Within the ﬁrst 100 days post-HSCT, all CMV-positive
recipients (þ /þ ) who received a transplant from a CMV-
seropositive donor developed a CMV-speciﬁc CD4þ T-cell
response, whereas 7/11 CMV-positive recipients (þ /)
with a seronegative donor and only 1/4 CMV-seronegative
recipients (/þ ) with a seropositive donor had a response.
In addition the magnitude of the CMV-speciﬁc CD4þ
T-cell response was greatest for þ /þ recipients, median
10.3 (0.6–103) cells/ml, followed by þ / recipients, median
0.4 (0–42) cells/ml and then /þ recipients, median 0
(0–0.7) (Kruskal–Wallis test, P¼ 0.01). The link between
serostatus and the CMV-speciﬁc CD4þ T-cell immunity
was observed throughout the period of study (P¼ 0.02).
This trend was also true for the CMV-speciﬁc CD8þ T-cell
response, although not statistically different (P¼ 0.08).
However, it should be noted that despite poor CMV-
speciﬁc T-cell recovery in the seronegative patients there
were no episodes of CMV reactivation within this group
(data not shown).
Poor CMV-speciﬁc T-cell recovery was observed in
recipients of MUD grafts in comparison to sibling
recipients (median value p0.1 vs X11.1; Po0.01). Only
two of the nine MUD recipients developed a CMV-speciﬁc
T-cell response in the ﬁrst 100 days post transplant but this
Table 2 Clinical features and CMV-speciﬁc immunity in CMV-reactivated HSCT patients
Patient ID Patient/Donor CMV
serostatus
Conditioning Sibling
(Sib)/MUD
Day (d) or period of
reactivationa
Peak CMV-speciﬁc
CD4 30–50 days
Peak CMV-speciﬁc
CD8 30–50 days
PT1 +/+ Non-mye. Sib o29 ND ND
PT2 +/+ Non-mye. Sib o100 ND ND
PT3 +/+ Non-mye. Sib o100 3 ND
PT4 +/+ Non-mye. Sib o20 11.6 ND
PT10 +/ Mye. Sib 42 7.6 58.3
PT11 +/+ Mye. Sib 80 o0.01 ND
PT12 +/+ Non-mye. Sib 30–44 1.6 169
PT16 +/+ Non-mye. Sib 40 9.1 8.1
PT18 +/+ Mye. MUD 14–24 0.6 ND
PT20 +/+ Mye. MUD 40 0.2 ND
PT25 +/+ Non-mye. Sib 21 o0.01 27.7
PT26 +/ Mye. Sib 53–66 ND 126
PT30 +/+ Non-mye. Sib 42–59 0.5 0.03
PT31 +/ Non-mye. Sib 35–52 ND ND
PT8 +/ Mye. Sib 43–72 0.17 o0.01
143–167
PT27 +/+ Non-mye. Sib 51 3.4 ND
83
PT28 +/ Mye. MUD 29–75, ND ND
135–162
PT29 +/ Non-mye. Sib 36 0.1 ND
51–61
PT19 +/ Mye. MUD 30 ND 0.16
73
162
Abbreviations: MUD¼matched unrelated donor; Mye.¼myeloablative conditioning; ND¼not done.
aoExact date of reactivation not known but occurred less than speciﬁed day post-SCT.
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was extremely weak (0.2 and 0.6 cell/ml; Table 2) and both
patients experienced viral reactivation. Of the remaining
seven transplant pairs with no CMV-speciﬁc immunity,
three patients were seronegative and did not reactivate,
possibly relating to low viral load; the other four patients
were CMV seropositive with CMV seronegative donors
and two of these did reactivate CMV without a detectable
immune response. Myeloablative or non-myeloablative
transplant conditioning did not have a signiﬁcant effect
on CMV-speciﬁc CD4þ and CD8þ T-cell reconstitution
and a non-signiﬁcant increase in the median value was
observed in the non-myeloablative group (2.3 (0–169) vs
10.3 (0–103) and 13.9 (0.02–143) vs 17.5 (0–262) for CMV-
speciﬁc CD4þ and CD8þ T-cell response, respectively).
CMV-speciﬁc CD4þ T cells show impaired production of
IL-2 for the ﬁrst 6 months following SCT
IL-2 production is important for sustaining T-cell expan-
sion and is produced following initial T-cell priming and
also by central memory T cells. In contrast an IFN-gþ
IL2-cytokine proﬁle is typical of cells with an effector
memory phenotype.18 Cytokine production by CMV-
speciﬁc CD4þ T cells was determined by ﬂow cytometry
after stimulation with CMV lysate. No detectable produc-
tion of IL-2 by CMV-speciﬁc T cells was observed in the
ﬁrst 4 weeks following transplantation. IL-2 production did
increase thereafter and the ratio of IL-2/IFN-g production
by CMV-speciﬁc T cells at different time points is shown in
Figure 4. This ratio increased after 50 days but was still less
than 50% before day 180. After 180 days over half of all
CMV-speciﬁc CD4þ T cells showed IL-2 production,
which is typical of the proﬁle observed in healthy non-SCT
donors. Unlike IFN-g production by CMV-speciﬁc CD4þ
T cells, IL-2 was not associated with reduced CMV
reactivation in the ﬁrst 100 days post transplant (data not
shown).
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Figure 2 A lower number of CMV-speciﬁc T cells is associated with more
than one CMV episode. The peak value of CMV-speciﬁc T cells (y axis) in
ﬁrst 100 days post transplantation was compared between patients with one
CMV episode and those with more than one episode (x axis) for CD4-
speciﬁc (a) and CD8-speciﬁc (b) T cells and analysed using the Mann–
Whitney U-test for signiﬁcance. *Indicates a signiﬁcant difference
(Po0.05) between 1 vs more than 1 CMV episode.
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Figure 1 CMV-speciﬁc T-cell response in patients with and without
CMV reactivation at different time periods. (a) Higher frequency of CMV-
speciﬁc CD4þ T cells between days 30 and 50 is associated with protection
from CMV reactivation. The number of CD4þ T cells responding to CMV
lysate within peripheral blood was assessed by intracellular cytokine
staining (ICS; y axis). These measurements were made on samples collected
between days 30 and 50, 80 and 100 and 180 and 200 (x axis) post
transplantation. *Indicates Po0.05 (Mann–Whitney U-test) between the
two groups, CMV reactivated (solid circles) vs non-reactivated (open
circles). (b) No difference in number of CMV-speciﬁc CD8þ T cells and
CMV reactivation status. HLA-class I tetramers spanning a wide number
of HLA types and the CMV proteins pp65, immediate early Ag (IE-1) and
pp50 proteins were used to determine the number of CMV-speciﬁc CD8þ
T cells (y axis) at different time periods post transplant (x axis). CMV
reactivated (solid circles) vs non-reactivated (open circles).
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CD8þ T-cell immunity to IE-1 is suppressed in the ﬁrst
100 days after transplantation
The magnitude and speciﬁcity of the CMV-speciﬁc CD8
T-cell immune response was assessed by staining of PBMC
with HLA-peptide tetramers containing a range of indivi-
dual peptides from the immunodominant CMV proteins
pp65, pp50 and IE-1. To determine the hierarchy of
immunodominance against these proteins the number
of CD8þ T cells staining with each tetramer was
determined at o100 days and 4100 days post transplant
(Figure 5). The magnitude of the CD8þ T-cell responses to
pp65 and pp50 were comparable (mean 36 vs 43 cells/ml) but
responses to IE-1 were ﬁve times lower (mean 7.2 cells/ml)
within the ﬁrst 100 days post transplantation. After 100
days the IE-1-speciﬁc CD8þ T-cell count increased and
comparable immune levels were seen against all three
proteins.
Discussion
Reactivation of CMV remains a signiﬁcant clinical problem
following allogeneic SCT despite improvements in antiviral
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Figure 3 Inﬂuence of the overall T-cell recovery on CMV-speciﬁc T-cell reconstitution. Within the ﬁrst 100-day period post transplant the peak T-cell
count (x axis) vs the CMV-speciﬁc T-cell count (y axis) was compared using the Spearman rank correlation test for CD4 (a) and CD8 (b) T cells.
(c) Correlation between CMV-speciﬁc CD4þ and CD8þ T-cell response. The number of CMV-speciﬁc CD4þ T cells (x axis) was compared to the number
of CMV-speciﬁc CD8þ T-cell response (y axis) using the Spearman rank correlation test. The P-value indicates level of signiﬁcance and r, the correlation
coefﬁcient.
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Figure 4 Conversion from effector memory to central memory CD4þ T
cells occurs during immune reconstitution post transplant. The ratio of
IL-2 to IFN-g production within CMV-speciﬁc CD4þ T cells (y axis) was
analysed in relation to the time post transplant (x axis). The mean with s.e.
bar is for ﬁve patients measured at the four different time periods.
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Figure 5 Analysis of the antigenic speciﬁcity of the CD8þ T-cell
response to CMV. CMV-speciﬁc class I tetramers were generated using
peptides from three different CMV proteins (pp65, pp50 and immediate
early Ag (IE-1)). The peak CMV-speciﬁc response for each protein is
represented for each patient at time pointso100 days and4100 days post
transplant. A signiﬁcant difference in CMV-speciﬁc CD8þ T cells is
indicated * between pp65 and IE-1 (o100 days) using the Kruskal–Wallis
test and Dunn’s post-test. Bars represent the mean.
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therapy.19 The nature of the conditioning regimen plays a
major role in determining the risk of viral reactivation and
T-cell depletion of the donor stem cell infusion is associated
with a particularly high risk of viraemia. There remains
debate as to the relative risk of CMV reactivation following
non-myeloablative transplantations in comparison to
myeloablative programmes20 and CMV-speciﬁc T-cell
immune reconstitution can occur promptly even after
alemtuzumab-containing conditioning regimens.21 In our
cohort reactivation occurred only in CMV seropositive
patients and conﬁrmed similar studies showing the primacy
of patient serostatus over donor graft origin in develop-
ment of viraemia.22
Relatively few studies have studied the importance of
both CMV-speciﬁc CD4þ and CD8þ T-cell immune
reconstitution in relation to reactivation risk. Most reports
have focussed on the CD8þ CMV-speciﬁc T-cell response
and demonstrate that robust CD8þ immune reconstitu-
tion is associated with a reduction in both CMV reactiva-
tion and disease.6,23,24 These studies have incorporated a
variety of techniques including in vitro expansion of
effector populations and staining with HLA-peptide tetra-
mers. We have used CMV lysate as an antigenic stimulus to
identify CMV-speciﬁc CD4þ T cells in the peripheral
blood of patients following SCT. This technique is being
used widely in the identiﬁcation of these cells in healthy
immunocompetent donors and has demonstrated that the
CMV-speciﬁc CD4þ T-cell response is dominated by large
oligoclonal expansions of cells with cytotoxic activity and
predominant production of IFN-g.25,26 These cells have
been shown to expand with age and display many
phenotypic and functional characteristics in common with
CD8þ T-cell populations. In HSCT, several studies have
demonstrated the importance of both the CD4þ and
CD8þ CMV-speciﬁc T cells in protection from CMV
reactivation.27,28 More recently, Lilleri proposed that an
absolute CD4 and CD8 count of 1 and 3 cells/ml,
respectively, may be valuable in protection from recurrent
CMV reactivation in young HSCT patients.14
Our data shows a clear association between reconstitu-
tion of the CD4þ CMV-speciﬁc T-cell immune response
within the ﬁrst 50 days and protection against CMV
reactivation. Patients who experienced CMV reactivation
displayed a mean CMV-speciﬁc CD4 response of 0.4 cells/
ml, which was 16 times lower than that seen in patients
without reactivation. It was not possible to discern an
absolute speciﬁc CD4þ T-cell response that was associated
with protection from reactivation and no CMV-speciﬁc
CD4þ T-cell response was observed in two patients
despite absence of viral reactivation. In this regard, it must
be appreciated that CMV lysate contains only a proportion
of the total CMV proteome and it is likely that a
component of the CMV-speciﬁc CD4þ T-cell response is
therefore not detected by this methodology. Avetisyan
et al.13 have reported that the total CMV-speciﬁc T-cell
response at 4 weeks correlates inversely with subsequent
CMV viral load but did not demonstrate a speciﬁc
protective role for the CD4þ population. In this study,
the CD8þ CMV-speciﬁc T-cell response was not predictive
of protection from a single episode of viral reactiva-
tion and suggests that the efﬁcient reconstitution of
CD4þCMV-speciﬁc T cells plays a more important role
in the early period post transplantation. These ﬁndings are
comparable to studies in renal transplantation and HIV
infection where the magnitude of the CMV-speciﬁc CD4þ
immune response is highly correlated with protection from
viral disease.26,29
Late CMV disease is becoming an increasing problem
with current transplant conditioning regimens. In our study
we found that patients with a combination of poor CD4þ
and CD8þ CMV-speciﬁc T-cell responses within the ﬁrst
100 days post transplantation were at very high risk of
recurrent viral reactivation and this is likely to explain the
observation that T-cell lymphopenia during this time
period is also associated with recurrent activation.17 These
data potentially allow for the identiﬁcation of patients in
whom recurrent viral reactivation will be likely and can
thus direct appropriate antiviral therapy.
The absolute lymphocyte count has been shown to be a
powerful determinant of patient outcome in a variety of
settings in haematological malignancy. The magnitude of
the CMV-speciﬁc immune response is such that it has been
shown to have a positive inﬂuence on the total lymphocyte
count within peripheral blood, and this may be at least
partly reﬂected in our study.30 Lymphopenia is known to be
a predictive factor for CMV reactivation after allogeneic
transplantation11,31 and may potentially be used as a
surrogate marker for poor virus-speciﬁc immunity in
situations where technology for ascertaining the
CMV-speciﬁc immune response is not available.
The data showed a strong correlation between the
magnitude of the CMV-speciﬁc CD4þ and CD8þ T-cell
immune responses. Indeed the CMV-speciﬁc CD4þ and
CD8þ T-cell responses both represented 10% of their
respective T-cell repertoire. Such extreme immunodomi-
nance of CMV in the post transplant period has been
observed in other studies28 and may reﬂect the observation
of CMV latency and reactivation in myeloid DCs.32
The CMV-speciﬁc CD4þ T-cell immune response is
unusual in that the great majority of the population is
comprised of cytotoxic CD4 cells, a minority population
within the CD4þ T-cell repertoire. Cytotoxic CD4þ T
cells show very comparable phenotypic and functional
features with CD8þ cytotoxic T cells and this is reﬂected
in their cytokine production. Almost all CMV-speciﬁc
cytotoxic CD4þ T cells secrete IFN-g following antigenic
stimulation, with subpopulations also showing production
of tumour necrosis factor-a and IL-2. In young healthy
donors approximately half of the CMV-speciﬁc CD4þ
T-cell pool is capable of IL-2 production but this
proportion falls within the elderly population.33 The
mechanisms that determine the pattern of cytokine proﬁle
within cytotoxic CD4þ populations have not yet been
ascertained but at least a component of this subset is likely
to comprise central memory cells which are characterized
by IL-2 production. A notable feature of our ﬁndings was
the clear increase in the proportion of cells expressing IL-2
in the ﬁrst year following transplantation. The most likely
explanation for this ﬁnding is viral reactivation in the early
post transplant period could lead to the expansion of
effector memory CMV-speciﬁc CD4þ T-cell populations
even in the absence of clinically detectable viraemia.34 As
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viral reactivation becomes controlled, reversion of Ag-
speciﬁc populations into central memory and resting
memory phenotype could then occur. Alterations in general
immune homeostasis in the early post transplant period
may also impact on the cytokine proﬁle of effector
populations.
The study also allowed us to investigate the antigenic
speciﬁcity of the CD8þ T-cell response to CMV following
allogeneic transplantation. The majority of studies within
this area have focussed on the magnitude and function of
the CD8þ T-cell response to peptides derived from pp65, a
component of the viral matrix and an immunodominant Ag
for CD8þ T-cell immunity.35 In this study we were able to
use HLA-peptide tetramers which contain peptides derived
from an additional two immunodominant proteins from
within the CMV proteome. These included the IE-1, and
the immune response against this protein has been shown
to be an important determinant for control of CMV
reactivation following solid organ transplantation.36 Func-
tional differences between pp65 and IE-1-speciﬁc CD8þ T
cells have been reported in the SCT setting which may
inﬂuence their relative efﬁcacy in control of viral reactiva-
tion,37 however T-cell function could not be addressed here.
We also studied the CD8þ immune response to a peptide
from pp50 from which a number of potent immunodomi-
nant peptides have now been characterized. Using the panel
of tetramers we observed a decreased frequency to IE-1 at
less than 100 days in comparison to pp65 and pp50.
Interestingly Lacey et al.37 have also observed comparable
functional responses to pp50 and pp65 post-SCT, but
impaired responses to IE-1. The CD8þ immune response
to IE-1 peptides was not predictive of increased protection
from viral reactivation in our study supporting two other
HSCT studies38,39 but in contrast to other studies in solid
organ transplantation. However it should be noted that not
all patients had both o100 days and 4100 days samples
hence variation in CMV immune reconstitution in differing
HLA contexts could potentially explain our ﬁndings in the
small patient cohort.
In conclusion, our ﬁndings revealed that the magnitude
of the CMV-speciﬁc CD4þ T-cell immune response to
CMV in the ﬁrst 50 days following transplantation is
predictive of the risk of viral reactivation. Protection from
viral reactivation appears to be mediated through popula-
tions of effector memory CD4þ cells, as deﬁned according
to their cytokine proﬁle, producing high levels of IFN-g.
CD8þ immune reconstitution was not predictive of
reactivation at this early stage but poor recovery was
predictive of recurrent episodes of viral reactivation. These
ﬁndings may help to direct future forms of immunotherapy
to assist reconstitution of the CMV-speciﬁc immune
response and imply that techniques, which enhance both
CD4þ and CD8þ immune reconstitution may exhibit
enhanced level of clinical efﬁcacy.
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